Innovating Works

BI PHARMA GMBH

Desconocido
VICT3R: Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of ani...
2024-07-26 - 2028-02-29 | Financiado
INSPIRE: INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse... BOEHRINGER INGELHEIM PHARMA GMBH CO KG participó en un H2020: H2020-MSCA-ITN-2019 New drug candidates often have off-target effects resulting in adverse events, thus representing a major limitation for drug R&D. Safety Pha...
2019-08-19 - 2024-05-31 | Financiado
PROTON: Proton transport and proton coupled transport BOEHRINGER INGELHEIM PHARMA GMBH CO KG participó en un H2020: H2020-MSCA-ITN-2019 Secure, competitive, and sustainable energy production is a major challenge facing human societies. Biomimetic solutions such as the develop...
2019-08-09 - 2024-07-31 | Financiado
ENTRAIN: ENdoThelial macRophage Alliance In Neuroinflammation BOEHRINGER INGELHEIM PHARMA GMBH CO KG participó en un H2020: H2020-MSCA-ITN-2018 Neurological diseases cause enormous suffering and a great economic burden. Almost 20 million Europeans are affected by the most frequently...
2019-05-07 - 2023-04-30 | Financiado
EUROoC: Interdisciplinary training network for advancing Organ on a chip technology in Europe BOEHRINGER INGELHEIM PHARMA GMBH CO KG participó en un H2020: H2020-MSCA-ITN-2018 EUROoC will create a trans-European network of industrially oriented specialists fully trained in development and application of the emergin...
2018-08-21 - 2023-05-31 | Financiado
TICARDIO: Thrombo inflammation in cardiovascular disease BOEHRINGER INGELHEIM PHARMA GMBH CO KG participó en un H2020: H2020-MSCA-ITN-2018 The demographic change with aging populations places a heavy burden on health care systems worldwide. Despite all medical advances, age rema...
2018-08-20 - 2023-11-30 | Financiado
BIGCHEM: Big Data in Chemistry BOEHRINGER INGELHEIM PHARMA GMBH CO KG participó en un H2020: H2020-MSCA-ITN-2015 The advent of the big data era in chemistry and the life sciences requires the development of new computational analysis methods, which are...
2015-07-27 - 2019-12-31 | Financiado
eCHO Systems: Enhancing CHO by Mammalian Systems Biotechnology eCHO systems BOEHRINGER INGELHEIM PHARMA GMBH CO KG participó en un H2020: H2020-MSCA-ITN-2014 Chinese hamster (CHO) ovary cells are the production host for a +50 billion €/yr biopharmaceuticals market. Current CHO production platforms...
2014-12-05 - 2018-12-31 | Financiado
TRANSPOL: Transport and signalling in Polarized Cells BOEHRINGER INGELHEIM PHARMA GMBH CO KG participó en un FP7: Aberrant molecular signalling and intracellular trafficking are the molecular cause of many human diseases. TRANSPOL is an interdisciplinary...
Financiado
NEURASYNC: Academic Industrial Training Network on Alpha Synuclein related Brain Diseases BOEHRINGER INGELHEIM PHARMA GMBH CO KG participó en un FP7: Parkinson’s Disease (PD) is the second most common neurodegenerative disorder. It is characterized pathologically by the accumulation of agg...
Financiado
TS-EUROTRAIN: Interdisciplinary training network for Tourette Syndrome structuring European Training capacities f... BOEHRINGER INGELHEIM PHARMA GMBH CO KG participó en un FP7: There is a striking lack in structured and standardized training infrastructure for neurodevelopmental disorders across Europe. Such trainin...
Financiado
DISCO: From DISCOvery to products A next generation pipeline for the sustainable generation of high value... BOEHRINGER INGELHEIM PHARMA GMBH CO KG participó en un FP7: "Plant natural products have been utilised by human civilisation for millennia, providing vital medicines and essential dietary components....
Financiado
ALEXANDER: Mucus Permeating Nanoparticulate Drug Delivery Systems BOEHRINGER INGELHEIM PHARMA GMBH CO KG participó en un FP7: The objective of the ALEXANDER project is the identification of novel strategies (e.g., proteolytic enzyme strategy, thiomer strategy, zeta...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.